However, in selected patients with persistent suspicion of prostate cancer and (repeatedly) negative MRI results, PSMA-PET/CT may be beneficial by identifying lesions for targeted biopsy instead of random sampling. This evidence concerns the gene FOLH1 and prostate cancer.